Durable, exceptional response to temozolomide in a patient with extensive-stage small cell lung cancer (ES-SCLC) metastatic to brain-Reference-Cited by-同舟云学术

Durable, exceptional response to temozolomide in a patient with extensive-stage small cell lung cancer (ES-SCLC) metastatic to brain

Published:2017 Issue: Volume:10 Page:17-20
ISSN:2468-2942
Container-title:Cancer Treatment and Research Communications
language:en
Short-container-title:Cancer Treatment and Research Communications

Author:

Gay Carl M.,de Groot Patricia M.,Pietanza M. Catherine,Byers Lauren Averett

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference14 articles.

1. Small cell lung cancer: where do we go from here?;Byers;Cancer,2015

2. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress;Chute;J. Clin. Oncol.,1999

3. Risk of brain metastasis from small cell carcinoma of the lung related to length of survival and prophylactic irradiation;Komaki;Cancer Treat.,1981

4. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic cranial irradiation overview collaborative group;Auperin;N. Engl. J. Med.,1999

5. Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker;Pietanza;Clin. Cancer Res.,2012

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Challenges and future perspectives for the use of temozolomide in the treatment of SCLC;Cancer Treatment Reviews;2024-09

2. Apatinib inhibits the growth of small cell lung cancer via a mechanism mediated by VEGF, PI3K/Akt and Ki‐67/CD31;Journal of Cellular and Molecular Medicine;2021-09-30

3. Potential Novel Therapy Targets in Neuroendocrine Carcinomas of the Breast;Clinical Breast Cancer;2019-04

4. Autophagy modulates temozolomide-induced cell death in alveolar Rhabdomyosarcoma cells;Cell Death Discovery;2018-10-25

5. Temozolomide;Reactions Weekly;2018-01